Retrospective analysis of plasma exchange combined with glucocorticosteroids for the treatment of systemic lupus erythematosus-related acute pancreatitis in central China

Abstract

Systemic lupus erythematosus-related acute pancreatitis (SLEAP) has a poor prognosis with a high mortality. We described the clinical features of SLEAP, and discussed the feasibility of plasma exchange (PE) combined with glucocorticosteroids (GC) in short-term prognosis and possible mechanism in reducing serum inflammatory cytokine IL-6 and removing serum lipids. A retrospective study was performed by an independent rheumatologist. Medical records of SLEAP from March 2010 to December 2014 were retrieved from Tongji Hospital information system, and patients were divided into two groups according to whether PE therapy was adopted. Sixteen patients treated with PE in combination with GC were classified as group A, and the other 10 patients who were treated with merely GC were classified as group B. Patients’ clinical remission rate and average daily GC dosage after two-week therapy were compared between the two groups. Patients’ serum inflammatory cytokines and lipid concentration were compared between baseline and after two-week treatment in both groups. Pearson correlation test was performed to determine association between serum cytokines and Ranson score. SLEDAI score in group A patients at baseline (14.8±3.1) showed no statistical difference from that in group B (14.1±3.3). At baseline serum IL-6 levels had no significant difference between group A [13.14 (11.12, 16.57) mg/L] and group B [14.63 (11.37, 16.37) mg/L]; after two-week therapy IL-6 decreased significantly in group A [9.16 (7.93, 10.75)mg/L] while it did not show decreasing trend in group B [13.62 (9.29,17.63) mg/L]. Serum lipid concentration after two-week therapy in group A [(TC=5.02±0.53, TG=1.46±0.44) mmol/L] decreased significantly compared to baseline [(TC=6.11±0.50, TG=2.14±1.03) mmol/L], while similar tendency was not observed in group B. The remission rate after two-week therapy was higher in group A (70.0%) than in group B (25.0%). Acute pancreatitis (AP) was one of the clinical manifestations of active SLE. PE combined with GC could reduce serum IL-6 level, and remove serum lipid to improve short-term prognosis. Therefore, it might be a safe and effective way in treating SLEAP and was worth continuing to explore its feasibility.

References

[1] NesherG, BreuerGS, TempranoK, et al.. Lupus-associated pancreatitis. Semin Arthritis Rheum, 2006, 35(4): 260-267

[2] WangCH, YaoTC, HuangYL, et al.. Acute pancreatitis in pediatric and adult-onset systemic lupus erythematosus: a comparison and review of the literature. Lupus, 2011, 20(5): 443-452

[3] MasoodiI. The simultaneous incidence of acute pancreatitis and autoimmune hemolytic anemia: a rare duo in a patient with SLE. Ger Med Sci, 2014, 12: Doc12

[4] JiaY, OrtizA, McCallumR, et al.. Acute pancreatitis as the initial presentation of systematic lupus erythematosus. Case Rep Gastrointest Med, 2014571493

[5] KapoorD, MendezE, EspinozaLR. Corticosteroids and SLE pancreatitis. J Rheumatol, 1999, 26(4): 1011-1012

[6] ZanenS, BrandA, CatsA. Acute pancreatitis in systemic lupus erythematosus (SLE). Successful treatment with plasmapheresis after failure of prednisone. Clin Exp Rheumatol, 1983, 1(4): 341-4

[7] KolkA, HorneffG, WilgenbusKK, et al.. Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus—possible toxicity of immunosuppressive therapy. ClinExpRheumatol, 1995, 13(3): 399-403

[8] Garcia-ConsuegraJ, MerinoR, AlonsoA, et al.. Systemic lupus erythematosus: a case report with unusual manifestations and favourable outcome after plasmapheresis. Eur J Pediatr, 1992, 151(8): 581-582

[9] FeldJ, IsenbergD. Why and how should we measure disease activity and damage in lupus?. Presse Med, 2014, 43(2): e151-156

[10] FitzGeraldJD, GrossmanJM. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus, 1999, 8(8): 638-644

[11] BanksPA, FreemanML. Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol, 2006, 101(10): 2379-2400

[12] KuoDC, RiderAC, EstradaP, et al.. Acute Pancreatitis: What's the Score?. J Emerg Med, 2015, 48(6): 762-770

[13] MalaviyaAN, SharmaA, AgarwalD, et al.. Acute abdomen in SLE. Int J Rheum Dis, 2011, 14(1): 98-104

[14] PenalvaJC, MartinezJ, PascualE, et al.. Chronic pancreatitis associated with systemic lupus erythematosus in a young girl. Pancreas, 2003, 27(3): 275-277

[15] SinghR, SaundersB, ScopelitisE. Pancreatitis leading to thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a case report and review of literature. Lupus, 2003, 12(2): 136-139

[16] IkuraY, MatsuoT, OgamiM, et al.. Cytomegalovirus associated pancreatitis in a patient with systemic lupus erythematosus. J Rheumatol, 2000, 27(11): 2715-2717

[17] NietoY, RussP, EversonG, et al.. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone marrow transplantat, 2000, 26(1): 109-111

[18] YiGC, YoonKH, HwangJB. Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease. J Pediatr Gastroenterol Nutr, 2012, 15(4): 272-275

[19] Sadr-AzodiO, MattssonF, BexliusTS, et al.. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA, 2013, 173(6): 444-449

[20] BreuerGS, BaerA, DahanD, et al.. Lupus-associated pancreatitis. Autoimmun Rev, 2006, 5(5): 314-318

[21] MakolA, PetriM. Pancreatitis in systemic lupus erythematosus: frequency and associated factors-a review of the Hopkins Lupus Cohort. J Rheumatol, 2010, 37(2): 341-345

[22] TerzinV, FoldesiI, KovacsL, et al.. Association between autoimmune pancreatitis and systemic autoimmune diseases. World J Gastroenterol, 2012, 8(21): 2649-2653

[23] GregoricP, SijackiA, StankovicS, et al.. SIRS score on admission and initial concentration of IL-6 as severe acute pancreatitis outcome predictors. Hepatogastroenterology, 2010, 57(98): 349-353

[24] ZhangJ, NiuJ, YangJ. Interleukin-6, interleukin-8 and interleukin-10 in estimating the severity of acute pancreatitis: an updated meta-analysis. Hepatogastroenterology, 2014, 61(129): 215-220

[25] AounE, ChenJ, ReighardD, et al.. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. Pancreatology, 2009, 9(6): 777-785

[26] DongL, HuS, ChenF, et al.. Increased expression of ganglioside GM1 in peripheral CD⁴⁺ T cells correlates soluble form of CD30 in systemic lupus erythematosus patients. J Biomed Biotechnol, 2010569053

[27] AraiA, NogamiA, ImadomeK, et al.. Sequential monitoring of serum IL-6, TNF-alpha, and IFN-gamma levels in a CAEBV patient treated by plasma exchange and immunochemotherapy. Int J Hematol, 2012, 96(5): 669-673

[28] SadeghiM, DanielV, WangH, et al.. Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients. Transplantation, 2013, 95(8): 1021-1029

[29] NakaeH, AsanumaY, TajimiK. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. Ther Apher, 2002, 6(6): 419-424

[30] SzodorayP, HajasA, TothL, et al.. The beneficial effect of plasmapheresis in mixed connective tissue disease with coexisting antiphospholipid syndrome. Lupus, 2014, 23(10): 1079-1084

[31] YangY, YeY, LiangL, et al.. Systemic-lupus-erythematosus-related acute pancreatitis: a cohort from South China. Clin Dev Immunol, 2012568564

[32] HuangJL, HuangCC, ChenCY, et al.. Acute pancreatitis: an early manifestation of systemic lupus erythematosus. Pediatr Emerg Care, 1994, 10(5): 291-293